SPYRE THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SPYRE THERAPEUTICS, INC. (SYRE) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $38.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $38.40M, a 2.67% increase from fiscal 2024.
- SPYRE THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $37.40M, a 110.11% increase from fiscal 2023.
- SPYRE THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $17.80M, a 13.59% decline from fiscal 2022.
- SPYRE THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $20.60M, a 21.89% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $38.40M 10-K · filed 2026-02-19 |
| 2024-12-31 | $37.40M 10-K · filed 2026-02-19 |
| 2023-12-31 | $17.80M 10-K · filed 2026-02-19 |
| 2022-12-31 | $20.60M 10-K · filed 2025-02-27 |
| 2021-12-31 | $16.90M 10-K/A · filed 2024-11-18 |
| 2016-12-31 | $9.40M 10-K · filed 2017-03-23 |
| 2015-12-31 | $3.90M 10-K · filed 2017-03-23 |
| 2014-12-31 | $3.00M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |